Art. -Nr.: HY-15823

CAY10566

18 Cited Publications

Kundenbewertung

Based on 18 publication(s) in Google Scholar

CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC₅₀s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. CAY10566 also shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC₅₀=7.9 nM or 6.8 nM).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.93%
CAS. Nr.: 944808-88-2
Formel: C₁₈H₁₇ClFN₅O₂
Molecular Weight:389.81

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

CAY10566 Chemical Structure

CAS. Nr.: 944808-88-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (18)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 4.5 nM (SCD1 in mouse), 26 nM (SCD1 in human)^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
NCI-H1155	IC₅₀	<10 nM Compound: 4	Inhibition of SCD in human NCI-H1155 cells non-expressing CYP4F11 assessed as reduction in cell viability incubated for 96 hrs by cell titer Glo reagent based assay Inhibition of SCD in human NCI-H1155 cells non-expressing CYP4F11 assessed as reduction in cell viability incubated for 96 hrs by cell titer Glo reagent based assay	[PMID: 32787093]
NCI-H2122	IC₅₀	<10 nM Compound: 4	Inhibition of SCD in human NCI-H2122 cells expressing CYP4F11 assessed as reduction in cell viability incubated for 96 hrs by cell titer Glo reagent based assay Inhibition of SCD in human NCI-H2122 cells expressing CYP4F11 assessed as reduction in cell viability incubated for 96 hrs by cell titer Glo reagent based assay	[PMID: 32787093]

In Vitro

CAY10566 (0.0001-10 μM; 24 hours) concentration-dependently decreases Swiss 3T3 cell proliferation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:

Swiss 3T3 cells
Concentration:

0.0001, 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time:

24 hours
Result:

Swiss 3T3 cell proliferation was concentration-dependently decreased.

In Vivo

After establishment of palpable tumors, the mice are treated with vehicle or SCD1 inhibitor (2.5 mg/kg CAY10566 orally twice daily). The effect of SCD1 inhibition on the Akt-driven tumors is greater than on the Ras-driven tumors, with the mean tumor volume at day 13 or 14 post therapy, relative to untreated tumors, 0.5±0.04 and 0.67±0.05 respectively (P=0.01 for Ras-Akt comparison, by two-tailed t test)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 944808-88-2
Appearance Solid
Molecular Weight 389.81
Formel C₁₈H₁₇ClFN₅O₂
Color White to yellow
SMILES

CC1=NN=C(C2=NN=C(N3CCC(OC4=CC(F)=CC=C4Cl)CC3)C=C2)O1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (18)

All Cell Proliferation/Viability AssayWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Cancer Cell

Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma. [Abstract]

2026 Feb 9;44(2):383-404.e18. PMID: 41544627
Gastroenterology

Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis. [Abstract]

2024 Jan 24:S0016-5085(24)00064-7. PMID: 38272100
Nat Commun

Single-cell lipidomics with high structural specificity by mass spectrometry. [Abstract]

2021 May 17;12(1):2869. PMID: 34001877
Redox Biol

FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. [Abstract]

2021 Jan;38:101807. PMID: 33271455

CAY10566 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2021 Jan;38:101807. [Abstract]

FBW7 silencing PANC-1 and SW1990 cells were treated with RSL3 (2 μmol/L) or CAY10566 (5 μmol/L) for 48–72 h and then detected cell viability.

CAY10566 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2021 Jan;38:101807. [Abstract]

TEM imaging was conducted in FBW7T205A overexpressed PANC-1 cells. RSL3 (2 μmol/L) and CAY10566 (5 μmol/L) treated PANC-1 cells functioned as the positive control. Red arrows showed the shrunken mitochondria. Blue arrows showed lipid droplets. The values below the western blot band represent the relative mean gray values of three independent experiments. Gray values were calculated by Adobe Photoshop CS6.
Proc Natl Acad Sci U S A

Ovarian cancer cell fate regulation by the dynamics between saturated and unsaturated fatty acids. [Abstract]

2022 Oct 11;119(41):e2203480119. PMID: 36197994

CAY10566 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2203480119. [Abstract]

XBP1 splicing in OVCAR-5 cells cultured in low-serum conditions and treated with SCD inhibitor CAY10566 (0-24.3 nM) for 48 h.

CAY10566 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2203480119. [Abstract]

XBP1 splicing in primary cells from tumors of OC patients cultured in low-serum conditions and treated with 3 μM CAY10566 for 48 h or with 1 μM CAY10566 and 50 μM PA for 12 h.

CAY10566 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2203480119. [Abstract]

XBP1 splicing in OVCAR-5 cells cultured in medium containing low serum and treated with 21.6 nM CAY10566 and indicated doses of OA for 48 h.
Regen Biomater

Matrix stiffness boosts PDAC chemoresistance via SCD1-dependent lipid metabolic reprogramming. [Abstract]

2025 Jun 16:12:rbaf056. PMID: 40741620
Free Radic Biol Med

Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]

2024 Jun 19:S0891-5849(24)00531-8. PMID: 38906233
Anal Chem

13C-Isotope Tracing Structural Lipidomics for Resolving Phospholipid Metabolism Dynamics in Human Breast Cancer Cells. [Abstract]

2026 Jan 27;98(3):2401-2413. PMID: 41512137
Mol Cancer Ther

Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. [Abstract]

2025 Jun 4;24(6):920-930. PMID: 39834305
J Ethnopharmacol

Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]

2026 Feb 28:357:120890. PMID: 41232632
J Agric Food Chem

Bovine Stearoyl-CoA Desaturase 1 Promotes Adipogenesis by Activating the PPARγ Receptor. [Abstract]

2020 Oct 28;68(43):12058-12066. PMID: 33052678
Brain Res Bull

Inhibition of SCD1 attenuates neuroinflammation and brain injury after cerebral ischemia-reperfusion. [Abstract]

2025 Dec 20:111693. PMID: 41429330
Cancer Res Commun

Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer. [Abstract]

2023 Jun 20;3(6):1067-1077. PMID: 37377614
Toxicol Appl Pharmacol

Plasticizer acetyl triethyl citrate (ATEC) induces lipogenesis and obesity. [Abstract]

2024 Jan:482:116788. PMID: 38086441
Exp Eye Res

SREBP1-driven SCD1 protects retinal pigment epithelium from oxidative damage by activating the NRF2/GPX4 axis. [Abstract]

2026 May:266:110932. PMID: 41720386
bioRxiv

2026 Feb 1.
bioRxiv

2025 Aug 06.
Research (Wash D C)

Metabolic Pathway of Monounsaturated Lipids Revealed by In-Depth Structural Lipidomics by Mass Spectrometry. [Abstract]

2023:6:0087. PMID: 36951803

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (64.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Acetone : 10 mg/mL (25.65 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5654 mL

12.8268 mL

25.6535 mL

5 mM

0.5131 mL

2.5654 mL

5.1307 mL

10 mM

0.2565 mL

1.2827 mL

2.5654 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Masuda M, et al. Activating transcription factor 4 regulates stearate-induced vascular calcification. J Lipid Res. 2012 Aug;53(8):1543-52. [Content Brief]

[2]. Liu G, et al. Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors. J Med Chem. 2007 Jun 28;50(13):3086-100. [Content Brief]

[3]. Koeberle A, et al. Palmitoleate is a mitogen, formed upon stimulation with growth factors, and converted to palmitoleoyl-phosphatidylinositol. J Biol Chem. 2012 Aug 3;287(32):27244-54. [Content Brief]

[4]. Kamphorst JJ, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A. 2013 May 28;110(22):8882-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Acetone / DMSO	1 mM	2.5654 mL	12.8268 mL	25.6535 mL	64.1338 mL
	5 mM	0.5131 mL	2.5654 mL	5.1307 mL	12.8268 mL
	10 mM	0.2565 mL	1.2827 mL	2.5654 mL	6.4134 mL
	15 mM	0.1710 mL	0.8551 mL	1.7102 mL	4.2756 mL
	20 mM	0.1283 mL	0.6413 mL	1.2827 mL	3.2067 mL
	25 mM	0.1026 mL	0.5131 mL	1.0261 mL	2.5654 mL
DMSO	30 mM	0.0855 mL	0.4276 mL	0.8551 mL	2.1378 mL
	40 mM	0.0641 mL	0.3207 mL	0.6413 mL	1.6033 mL
	50 mM	0.0513 mL	0.2565 mL	0.5131 mL	1.2827 mL
	60 mM	0.0428 mL	0.2138 mL	0.4276 mL	1.0689 mL

Keywords

CAY10566

18 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CAY10566

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) CAY10566

Biologische Aktivität

Chemical Information

Publications (18)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CAY10566

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) CAY10566

Biologische Aktivität

Chemical Information

Publications (18)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CAY10566 Related Classifications

HY-15823 Related Classifications